
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...


